Alan W Stitt

List of Publications by Year in Descending Order

195 papers	10,412 citations	59 h-index	95 g-index
204 ext. papers	11,918 ext. citations	5.9 avg, IF	6.41 L-index

#	Paper	IF	Citations
195	Juxtavascular Microglia Scavenge Dying Pericytes and Vascular Smooth Muscle Cells in Diabetic Retinopathy. *International Journal of Translational Medicine*, **2022**, 2, 41-50		
194	Pericyte and Vascular Smooth Muscle Death in Diabetic Retinopathy Involves Autophagy. *International Journal of Translational Medicine*, **2022**, 2, 26-40		1
193	Common pathways in dementia and diabetic retinopathy: understanding the mechanisms of diabetes-related cognitive decline. *Trends in Endocrinology and Metabolism*, **2021**,	8.8	5
192	Targeting Plasma Kallikrein With a Novel Bicyclic Peptide Inhibitor (THR-149) Reduces Retinal Thickening in a Diabetic Rat Model **2021**, 62, 18		1
191	Current concepts on endothelial stem cells definition, location, and markers. *Stem Cells Translational Medicine*, **2021**, 10 Suppl 2, S54-S61	6.9	2
190	miR-130a activates the VEGFR2/STAT3/HIF1 axis to potentiate the vasoregenerative capacity of endothelial colony-forming cells in hypoxia. *Molecular Therapy - Nucleic Acids*, **2021**, 23, 968-981	10.7	1
189	Targeting RGD-binding integrins as an integrative therapy for diabetic retinopathy and neovascular age-related macular degeneration. *Progress in Retinal and Eye Research*, **2021**, 85, 100966	20.5	5
188	Current understanding of the molecular and cellular pathology of diabetic retinopathy. *Nature Reviews Endocrinology*, **2021**, 17, 195-206	15.2	53
187	Diabetic vascular hyperpermeability: optical coherence tomography angiography and functional loss assessments of relationships among retinal vasculature changes. *Scientific Reports*, **2021**, 11, 4185	4.9	1
186	NOX4 is a major regulator of cord blood-derived endothelial colony-forming cells which promotes post-ischaemic revascularization. *Cardiovascular Research*, **2020**, 116, 393-405	9.9	10
185	Claudin-5 Redistribution Induced by Inflammation Leads to Anti-VEGF-Resistant Diabetic Macular Edema. *Diabetes*, **2020**, 69, 981-999	0.9	25
184	Targeting QKI-7 in vivo restores endothelial cell function in diabetes. *Nature Communications*, **2020**, 11, 3812	17.4	12
183	Endothelial Cells Derived From Patients With Diabetic Macular Edema Recapitulate Clinical Evaluations of Anti-VEGF Responsiveness Through the Neuronal Pentraxin 2 Pathway. *Diabetes*, **2020**, 69, 2170-2185	0.9	3
182	Ocular Regeneration - Where are We and What s on the Horizon. *Current Eye Research*, **2020**, 45, 229	2.9	
181	Vascular Regeneration for Ischemic Retinopathies: Hope from Cell Therapies. *Current Eye Research*, **2020**, 45, 372-384	2.9	11
180	The Role of Lipoxidation in the Pathogenesis of Diabetic Retinopathy. *Frontiers in Endocrinology*, **2020**, 11, 621938	5.7	9
179	Intravitreal AAV2.COMP-Ang1 Attenuates Deep Capillary Plexus Expansion in the Aged Diabetic Mouse Retina **2019**, 60, 2494-2502		5

178	The Placental Growth Factor Pathway and Its Potential Role in Macular Degenerative Disease. *Current Eye Research*, **2019**, 44, 813-822	2.9	6
177	Attenuating Diabetic Vascular and Neuronal Defects by Targeting P2rx7. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	11
176	The vasoreparative potential of endothelial colony-forming cells in the ischemic retina is enhanced by cibinetide, a non-hematopoietic erythropoietin mimetic. *Experimental Eye Research*, **2019**, 182, 144-155	3.7	13
175	Involvement of TRPV1 and TRPV4 Channels in Retinal Angiogenesis **2019**, 60, 3297-3309		12
174	The RNA-binding protein QKI controls alternative splicing in vascular cells, producing an effective model for therapy. *Journal of Cell Science*, **2019**, 132,	5.3	12
173	CAMKII as a therapeutic target for growth factor-induced retinal and choroidal neovascularization. *JCI Insight*, **2019**, 4,	9.9	5
172	IL-33 deficiency causes persistent inflammation and severe neurodegeneration in retinal detachment. *Journal of Neuroinflammation*, **2019**, 16, 251	10.1	22
171	Enhanced Function of Induced Pluripotent Stem Cell-Derived Endothelial Cells Through ESM1 Signaling. *Stem Cells*, **2019**, 37, 226-239	5.8	9
170	The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases. *Progress in Retinal and Eye Research*, **2019**, 69, 116-136	20.5	38
169	The Vasoreparative Function of Myeloid Angiogenic Cells Is Impaired in Diabetes Through the Induction of IL1 *Stem Cells*, **2018**, 36, 834-843	5.8	13
168	Follistatin-Like 3 Enhances the Function of Endothelial Cells Derived from Pluripotent Stem Cells by Facilitating Catenin Nuclear Translocation Through Inhibition of Glycogen Synthase Kinase-3 Activity. *Stem Cells*, **2018**, 36, 1033-1044	5.8	13
167	Neurodegeneration in diabetic retinopathy: does it really matter?. *Diabetologia*, **2018**, 61, 1902-1912	10.3	201
166	Preclinical Evaluation and Optimization of a Cell Therapy Using Human Cord Blood-Derived Endothelial Colony-Forming Cells for Ischemic Retinopathies. *Stem Cells Translational Medicine*, **2018**, 7, 59-67	6.9	23
165	The Vasoreparative Potential of Endothelial Colony Forming Cells: A Journey Through Pre-clinical Studies. *Frontiers in Medicine*, **2018**, 5, 273	4.9	26
164	Characterization of a Spontaneously Immortalized Murine M ller Glial Cell Line QMMuC-1 **2018**, 59, 1666-1674		10
163	Quaking Is a Key Regulator of Endothelial Cell Differentiation, Neovascularization, and Angiogenesis. *Stem Cells*, **2017**, 35, 952-966	5.8	36
162	The pathology associated with diabetic retinopathy. *Vision Research*, **2017**, 139, 7-14	2.1	151
161	MicroRNA-containing extracellular vesicles released from endothelial colony-forming cells modulate angiogenesis during ischaemic retinopathy. *Journal of Cellular and Molecular Medicine*, **2017**, 21, 3405-3419	5.6	28

160	Inhibition or deletion of 11β-HSD1 does not increase angiogenesis in ischemic retinopathy. *Diabetes and Metabolism*, **2017**, 43, 480-483	5.4	0
159	Endothelial Progenitors: A Consensus Statement on Nomenclature. *Stem Cells Translational Medicine*, **2017**, 6, 1316-1320	6.9	243
158	Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. *JCI Insight*, **2017**, 2,	9.9	374
157	Animal Models of Retinal Vein Occlusion **2017**, 58, 6175-6192		20
156	Posterior drug delivery via periocular route: challenges and opportunities. *Therapeutic Delivery*, **2017**, 8, 685-699	3.8	22
155	The progress in understanding and treatment of diabetic retinopathy. *Progress in Retinal and Eye Research*, **2016**, 51, 156-86	20.5	449
154	200 Dedifferentiated or Reborn Again? Elucidating The Chromatin Remodelling Mechanisms During Endothelial Cell Reprogramming for Cardiovascular Therapy. *Heart*, **2016**, 102, A134.2-A134	5.1	
153	Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 7213-8	11.5	40
152	Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis. *Journal of Biological Chemistry*, **2016**, 291, 7242-55	5.4	28
151	Animal Models of Diabetic Retinopathy. *Essentials in Ophthalmology*, **2016**, 67-83	0.2	3
150	Cathepsin S Cleavage of Protease-Activated Receptor-2 on Endothelial Cells Promotes Microvascular Diabetes Complications. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 1635-49	12.7	42
149	Hypoxia-induced responses by endothelial colony-forming cells are modulated by placental growth factor. *Stem Cell Research and Therapy*, **2016**, 7, 173	8.3	6
148	Endothelial cell-derived pentraxin 3 limits the vasoreparative therapeutic potential of circulating angiogenic cells. *Cardiovascular Research*, **2016**, 112, 677-688	9.9	18
147	Role of the receptor for advanced glycation endproducts (RAGE) in retinal vasodegenerative pathology during diabetes in mice. *Diabetologia*, **2015**, 58, 1129-37	10.3	48
146	Intravitreal AAV2.COMP-Ang1 Prevents Neurovascular Degeneration in a Murine Model of Diabetic Retinopathy. *Diabetes*, **2015**, 64, 4247-59	0.9	44
145	MicroRNA-199b Modulates Vascular Cell Fate During iPS Cell Differentiation by Targeting the Notch Ligand Jagged1 and Enhancing VEGF Signaling. *Stem Cells*, **2015**, 33, 1405-18	5.8	47
144	Abnormal Glycogen Storage by Retinal Neurons in Diabetes **2015**, 56, 8008-18		3
143	Epigenetic Changes in Endothelial Progenitors as a Possible Cellular Basis for Glycemic Memory in Diabetic Vascular Complications. *Journal of Diabetes Research*, **2015**, 2015, 436879	3.9	39

142	Differentiation of human pluripotent stem cells to cells similar to cord-blood endothelial colony-forming cells. *Nature Biotechnology*, **2014**, 32, 1151-1157	44.5	164
141	RAGE regulates immune cell infiltration and angiogenesis in choroidal neovascularization. *PLoS ONE*, **2014**, 9, e89548	3.7	17
140	Angiogenic potential of vitreous from Proliferative Diabetic Retinopathy and Eales' Disease patients. *PLoS ONE*, **2014**, 9, e107551	3.7	28
139	Endothelial progenitor cells in diabetic retinopathy. *Frontiers in Endocrinology*, **2014**, 5, 44	5.7	56
138	The role of immune-related myeloid cells in angiogenesis. *Immunobiology*, **2013**, 218, 1370-5	3.4	61
137	Characterisation and therapeutic potential of endothelial progenitor cells. *Lancet, The*, **2013**, 381, S73	40	2
136	Therapeutic potential of targeting lipid aldehydes and lipoxidation end-products in the treatment of ocular disease. *Future Medicinal Chemistry*, **2013**, 5, 189-211	4.1	6
135	Advances in our understanding of diabetic retinopathy. *Clinical Science*, **2013**, 125, 1-17	6.5	121
134	Raman spectroscopy for the detection of AGEs/ALEs. *Methods in Molecular Biology*, **2013**, 965, 297-312	1.4	5
133	Activation of the ACE2/angiotensin-(1-7)/Mas receptor axis enhances the reparative function of dysfunctional diabetic endothelial progenitors. *Diabetes*, **2013**, 62, 1258-69	0.9	83
132	Ex vivo expansion of human outgrowth endothelial cells leads to IL-8-mediated replicative senescence and impaired vasoreparative function. *Stem Cells*, **2013**, 31, 1657-68	5.8	43
131	Advanced glycation end products and diabetic retinopathy. *Current Medicinal Chemistry*, **2013**, 20, 3234-40	4.3	84
130	Harnessing Endothelial Progenitor Cells for Therapeutic Angiogenesis **2013**, 445-458		
129	Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. *Diabetologia*, **2012**, 55, 845-54	10.3	111
128	The pathogenic role of Maillard reaction in the aging eye. *Amino Acids*, **2012**, 42, 1205-20	3.5	104
127	Proteomic profiling of human retinal pigment epithelium exposed to an advanced glycation-modified substrate. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2012**, 250, 349-59	3.8	14
126	Therapeutic revascularisation of ischaemic tissue: the opportunities and challenges for therapy using vascular stem/progenitor cells. *Stem Cell Research and Therapy*, **2012**, 3, 31	8.3	23
125	Bone marrow-CNS connections: implications in the pathogenesis of diabetic retinopathy. *Progress in Retinal and Eye Research*, **2012**, 31, 481-94	20.5	43

124	A Review of Patents Relating to Therapeutic Angiogenesis Using Endothelial Progenitors and Other Vasculogenesis-Related Cell Types. *Recent Patents on Regenerative Medicine*, **2012**, 3, 63-73		
123	Profiling retinal biochemistry in the MPDZ mutant retinal dysplasia and degeneration chick: a model of human RP and LCA **2012**, 53, 413-20		7
122	Deep sequencing reveals predominant expression of miR-21 amongst the small non-coding RNAs in retinal microvascular endothelial cells. *Journal of Cellular Biochemistry*, **2012**, 113, 2098-111	4.7	56
121	Endothelial progenitors as tools to study vascular disease. *Stem Cells International*, **2012**, 2012, 346735	5	22
120	Natural history of age-related retinal lesions that precede AMD in mice fed high or low glycemic index diets **2012**, 53, 622-32		42
119	Myeloid angiogenic cells act as alternative M2 macrophages and modulate angiogenesis through interleukin-8. *Molecular Medicine*, **2011**, 17, 1045-55	6.2	137
118	Sclera as a surrogate marker for determining AGE-modifications in Bruch's membrane using a Raman spectroscopy-based index of aging **2011**, 52, 1593-8		23
117	Vascular stem cells and ischaemic retinopathies. *Progress in Retinal and Eye Research*, **2011**, 30, 149-66	20.5	58
116	Diabetes-related adduct formation and retinopathy. *Journal of Ocular Biology, Diseases, and Informatics*, **2011**, 4, 10-8		14
115	M□ller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products. *Diabetologia*, **2011**, 54, 690-8	10.3	86
114	AGEs, RAGE, and diabetic retinopathy. *Current Diabetes Reports*, **2011**, 11, 244-52	5.6	143
113	Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy. *Diabetes*, **2011**, 60, 2995-3005	0.9	88
112	Differences in mouse models of diabetes mellitus in studies of male reproduction. *Journal of Developmental and Physical Disabilities*, **2010**, 33, 709-16		19
111	Multiplex analysis of age-related protein and lipid modifications in human Bruch's membrane. *FASEB Journal*, **2010**, 24, 4816-4824	0.9	0
110	Differential modulation of angiogenesis by erythropoiesis-stimulating agents in a mouse model of ischaemic retinopathy. *PLoS ONE*, **2010**, 5, e11870	3.7	18
109	Multiplex analysis of age-related protein and lipid modifications in human Bruch's membrane. *FASEB Journal*, **2010**, 24, 4816-24	0.9	47
108	Outgrowth endothelial cells: characterization and their potential for reversing ischemic retinopathy **2010**, 51, 5906-13		128
107	AGEs and diabetic retinopathy **2010**, 51, 4867-74		145

106	Effects of an endothelin receptor antagonist on a model of hypertensive retinopathy. *Ophthalmic Research*, **2010**, 43, 99-107	2.9	4
105	Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. *Journal of Biological Chemistry*, **2010**, 285, 23137-46	5.4	91
104	Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced glycation end-products (RAGE). *Diabetologia*, **2010**, 53, 2656-66	10.3	126
103	Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities. *BMC Medical Genomics*, **2010**, 3, 18	3.7	221
102	Proteomic profiling of the retinal dysplasia and degeneration chick retina. *Molecular Vision*, **2010**, 16, 7-17	2.3	14
101	Evidence supporting a role for N-(3-formyl-3,4-dehydropiperidino)lysine accumulation in Müller glia dysfunction and death in diabetic retinopathy. *Molecular Vision*, **2010**, 16, 2524-38	2.3	39
100	Retinal endothelial cell apoptosis stimulates recruitment of endothelial progenitor cells **2009**, 50, 4967-73		20
99	Advanced glycation end product (AGE) accumulation on Bruch's membrane: links to age-related RPE dysfunction **2009**, 50, 441-51		65
98	Upregulation of oxidative stress markers in human microvascular endothelial cells by complexes of serum albumin and digestion products of glycated casein. *Journal of Biochemical and Molecular Toxicology*, **2009**, 23, 364-72	3.4	20
97	Effect of signal intensity normalization on the multivariate analysis of spectral data in complex real-world datasets. *Journal of Raman Spectroscopy*, **2009**, 40, 429-435	2.3	32
96	Advanced glycation end products accumulate in the reproductive tract of men with diabetes. *Journal of Developmental and Physical Disabilities*, **2009**, 32, 295-305		68
95	Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis?. *Eye*, **2009**, 23, 1496-508	4.4	228
94	The role of advanced glycation end products in retinal ageing and disease. *Biochimica Et Biophysica Acta - General Subjects*, **2009**, 1790, 1109-16	4	85
93	Advanced glycation of the Arg-Gly-Asp (RGD) tripeptide motif modulates retinal microvascular endothelial cell dysfunction. *Molecular Vision*, **2009**, 15, 1509-20	2.3	15
92	Protein expression profiling during chick retinal maturation: a proteomics-based approach. *Proteome Science*, **2008**, 6, 34	2.6	18
91	A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats. *British Journal of Ophthalmology*, **2008**, 92, 545-7	5.5	34
90	Advanced glycation of fibronectin impairs vascular repair by endothelial progenitor cells: implications for vasodegeneration in diabetic retinopathy. *Investigative Ophthalmology and Visual Science*, **2008**, 49, 1232-41		54
89	Evaluation of N (epsilon)-(3-formyl-3,4-dehydropiperidino)lysine as a novel biomarker for the severity of diabetic retinopathy. *Diabetologia*, **2008**, 51, 1723-30	10.3	24

88	Raman spectroscopy of advanced glycation end products (AGEs), possible markers for progressive retinal dysfunction. *Journal of Raman Spectroscopy*, **2008**, 39, 1635-1642	2.3	24
87	Advanced glycation as a basis for understanding retinal aging and noninvasive risk prediction. *Annals of the New York Academy of Sciences*, **2008**, 1126, 59-65	6.5	20
86	The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. *PLoS ONE*, **2008**, 3, e2584	3.7	43
85	The Role of Advanced Glycation in Diabetic Retinopathy **2008**, 187-206		
84	Kv1.5 is a major component underlying the A-type potassium current in retinal arteriolar smooth muscle. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 292, H1001-8	5.2	25
83	Arteriolar involvement in the microvascular lesions of diabetic retinopathy: implications for pathogenesis. *Microcirculation*, **2007**, 14, 25-38	2.9	135
82	Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina. *Diabetologia*, **2007**, 50, 1089-98	10.3	60
81	Recombinant alpha2(IV)NC1 domain of type IV collagen is an effective regulator of retinal capillary endothelial cell proliferation and inhibits pre-retinal neovascularisation. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2007**, 245, 581-7	3.8	3
80	New developments in diabetic retinopathy. *Expert Review of Ophthalmology*, **2007**, 2, 947-956	1.5	
79	Confocal Raman microscopy can quantify advanced glycation end product (AGE) modifications in Bruch's membrane leading to accurate, nondestructive prediction of ocular aging. *FASEB Journal*, **2007**, 21, 3542-52	0.9	92
78	AGE and RAGE inhibitors in the treatment of diabetic retinopathy. *Expert Review of Ophthalmology*, **2007**, 2, 105-120	1.5	5
77	Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. *Experimental Diabetes Research*, **2007**, 2007, 51837		52
76	Distribution of the receptor for advanced glycation end products in the human male reproductive tract: prevalence in men with diabetes mellitus. *Human Reproduction*, **2007**, 22, 2169-77	5.7	77
75	Functional Anatomy, Fine Structure and Basic Pathology of the Retinal Vasculature **2007**, 3-23		4
74	Rod photoreceptor loss in Rho-/- mice reduces retinal hypoxia and hypoxia-regulated gene expression. *Investigative Ophthalmology and Visual Science*, **2006**, 47, 5553-60		34
73	Involvement of MAPKs in endostatin-mediated regulation of blood-retinal barrier function. *Current Eye Research*, **2006**, 31, 1033-45	2.9	27
72	Retinopathy is reduced during experimental diabetes in a mouse model of outer retinal degeneration. *Investigative Ophthalmology and Visual Science*, **2006**, 47, 5561-8		108
71	Endostatin modulates VEGF-mediated barrier dysfunction in the retinal microvascular endothelium. *Experimental Eye Research*, **2005**, 81, 22-31	3.7	24

70	Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. *American Journal of Pathology*, **2005**, 166, 637-44	5.8	156
69	Characterization of a Glycoaldehyde-Modified Model of the Diabetic Basement Membrane: Relevance to Pathological Responses during Diabetes. *Annals of the New York Academy of Sciences*, **2005**, 1043, 931-931	6.5	
68	Quantification of Advanced Glycation End Products in Diabetic Animal Tissues by RP-HPLC: An Investigation of the Role of Pyridoxamine. *Annals of the New York Academy of Sciences*, **2005**, 1043, 944-944	6.5	
67	The maillard reaction in eye diseases. *Annals of the New York Academy of Sciences*, **2005**, 1043, 582-97	6.5	86
66	Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium. *British Journal of Ophthalmology*, **2005**, 89, 107-12	5.5	29
65	Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3. *Diabetes*, **2005**, 54, 785-94	0.9	97
64	Gremlin gene expression in bovine retinal pericytes exposed to elevated glucose. *British Journal of Ophthalmology*, **2005**, 89, 1638-42	5.5	32
63	Advanced glycation and retinal pathology during diabetes. *Pharmacological Reports*, **2005**, 57 Suppl, 156-68	3.9	22
62	Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat. *Diabetologia*, **2004**, 47, 1385-95	10.3	65
61	Substrates modified by advanced glycation end-products cause dysfunction and death in retinal pericytes by reducing survival signals mediated by platelet-derived growth factor. *Diabetologia*, **2004**, 47, 1735-46	10.3	50
60	Chloroquine causes lysosomal dysfunction in neural retina and RPE: implications for retinopathy. *Current Eye Research*, **2004**, 28, 277-84	2.9	72
59	Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. *American Journal of Pathology*, **2004**, 164, 1263-73	5.8	99
58	Advanced glycation and advanced lipoxidation: possible role in initiation and progression of diabetic retinopathy. *Current Pharmaceutical Design*, **2004**, 10, 3349-60	3.3	35
57	Ocular wounding prevents pre-retinal neovascularization and upregulates PEDF expression in the inner retina. *Molecular Vision*, **2004**, 10, 432-8	2.3	17
56	Advanced glycation endproduct modified basement membrane attenuates endothelin-1 induced [Ca2+]i signalling and contraction in retinal microvascular pericytes. *Molecular Vision*, **2004**, 10, 996-1004	2.3	15
55	The role of advanced glycation end products in retinal microvascular leukostasis. *Investigative Ophthalmology and Visual Science*, **2003**, 44, 4457-64		141
54	Prevention of retinal capillary basement membrane thickening in diabetic dogs by a non-steroidal anti-inflammatory drug. *Diabetologia*, **2003**, 46, 1269-75	10.3	23
53	The role of advanced glycation in the pathogenesis of diabetic retinopathy. *Experimental and Molecular Pathology*, **2003**, 75, 95-108	4.4	177

52	Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes. *Journal of Pathology*, **2003**, 201, 328-33	9.4	78
51	Characterisation of WE-14 in porcine ocular tissue. *Regulatory Peptides*, **2003**, 113, 41-7		8
50	Role of vascular endothelial growth factor and placental growth factors during retinal vascular development and hyaloid regression. *Investigative Ophthalmology and Visual Science*, **2003**, 44, 839-47		64
49	Sources of PDGF expression in murine retina and the effect of short-term diabetes. *Molecular Vision* , **2003**, 9, 665-72	2.3	18
48	Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho(-/-) mice. *Human Molecular Genetics*, **2002**, 11, 547-57	5.6	104
47	Murine model of autosomal dominant retinitis pigmentosa generated by targeted deletion at codon 307 of the rds-peripherin gene. *Human Molecular Genetics*, **2002**, 11, 1005-16	5.6	34
46	Anti-angiogenic therapy for uveal melanoma--more haste, less speed. *British Journal of Ophthalmology*, **2002**, 86, 368-9	5.5	9
45	Synthetic peptides interacting with the 67-kd laminin receptor can reduce retinal ischemia and inhibit hypoxia-induced retinal neovascularization. *American Journal of Pathology*, **2002**, 160, 307-13	5.8	31
44	Advanced glycation end products and diabetic complications. *Expert Opinion on Investigational Drugs*, **2002**, 11, 1205-23	5.9	94
43	The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. *Diabetes*, **2002**, 51, 2826-32	0.9	295
42	Role of dyslipidemia and AGE/ALE formation in the progression of nephropathy and retinopathy in STZ-diabetic rats. *International Congress Series*, **2002**, 1245, 169-173		1
41	Advanced glycation: an important pathological event in diabetic and age related ocular disease. *British Journal of Ophthalmology*, **2001**, 85, 746-53	5.5	239
40	Expression of the 67 kDa laminin receptor (67LR) during retinal development: correlations with angiogenesis. *Experimental Eye Research*, **2001**, 73, 81-92	3.7	19
39	Advanced glycation alters expression of the 67kDa laminin receptor in retinal microvascular endothelial cells. *Life Sciences*, **2001**, 68, 2695-703	6.8	9
38	Differential expression of renal AGE-receptor genes in NOD mice: possible role in nonobese diabetic renal disease. *Kidney International*, **2000**, 58, 1931-40	9.9	59
37	Advanced glycation end-product receptor interactions on microvascular cells occur within caveolin-rich membrane domains. *FASEB Journal*, **2000**, 14, 2390-2	0.9	44
36	The expression of membrane-associated 67-kDa laminin receptor (67LR) is modulated in vitro by cell-contact inhibition. *Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications*, **2000**, 3, 53-9		25
35	Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. *Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications*, **2000**, 3, 380-8		94

34	Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. *Biochemical and Biophysical Research Communications*, **1999**, 256, 549-56	3.4	94
33	Expression of the VEGF gene family during retinal vaso-obliteration and hypoxia. *Biochemical and Biophysical Research Communications*, **1999**, 262, 333-40	3.4	59
32	Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. *Journal of Pathology*, **1998**, 186, 306-12	9.4	67
31	Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. *Diabetes*, **1998**, 47, 945-52	0.9	200
30	Increased Levels of Advanced Glycation Endproducts in the Lenses and Blood Vessels of Cigarette Smokers. *Molecular Medicine*, **1998**, 4, 594-601	6.2	114
29	The 67-kd laminin receptor is preferentially expressed by proliferating retinal vessels in a murine model of ischemic retinopathy. *American Journal of Pathology*, **1998**, 152, 1359-65	5.8	25
28	Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy. *Investigative Ophthalmology and Visual Science*, **1998**, 39, 2517-23		87
27	Atherogenesis and advanced glycation: promotion, progression, and prevention. *Annals of the New York Academy of Sciences*, **1997**, 811, 115-27; discussion 127-9	6.5	75
26	An Investigation of Receptor-Mediated Endocytosis and Endosomal Sorting of Albumin and Transferrin in Retinal Vascular Endothelial Cells. *Endothelium: Journal of Endothelial Cell Research*, **1996**, 4, 113-118		1
25	Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 11047-52	11.5	291
24	Fasciola hepatica: disruption of the vitelline cells in vitro by the sulphoxide metabolite of triclabendazole. *Parasitology Research*, **1996**, 82, 333-9	2.4	35
23	Retinal and choroidal response to panretinal photocoagulation and ultrastructural perspective. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **1996**, 234, 349	3.8	1
22	Endothelin-like immunoreactivity and receptor binding in the choroid and retina. *Current Eye Research*, **1996**, 15, 111-7	2.9	42
21	Increased endocytosis in retinal vascular endothelial cells grown in high glucose medium is modulated by inhibitors of nonenzymatic glycosylation. *Diabetologia*, **1995**, 38, 1271-5	10.3	20
20	Retinal and choroidal responses to panretinal photocoagulation: an ultrastructural perspective. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **1995**, 233, 699-705	3.8	17
19	Irish college of ophthalmologists. *Irish Journal of Medical Science*, **1995**, 164, 329-340	1.9	
18	Diabetic retinopathy: morphometric analysis of basement membrane thickening of capillaries in different retinal layers within arterial and venous environments. *British Journal of Ophthalmology*, **1995**, 79, 1120-3	5.5	26
17	Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients. *British Journal of Ophthalmology*, **1995**, 79, 362-7	5.5	129

16	The effect of triclabendazole ("Fasinex") on protein synthesis by the liver fluke, Fasciola hepatica. *International Journal for Parasitology*, **1995**, 25, 421-9	4.3	28
15	Nitric oxide synthase activity and expression in retinal capillary endothelial cells and pericytes. *Current Eye Research*, **1995**, 14, 285-94	2.9	89
14	Selective loss of vascular smooth muscle cells in the retinal microcirculation of diabetic dogs. *British Journal of Ophthalmology*, **1994**, 78, 54-60	5.5	48
13	Diabetic retinopathy: quantitative variation in capillary basement membrane thickening in arterial or venous environments. *British Journal of Ophthalmology*, **1994**, 78, 133-7	5.5	57
12	The combined effects of diabetes and ionising radiation on the rat retina: an ultrastructural study. *Current Eye Research*, **1994**, 13, 79-86	2.9	13
11	The effect of the sulphoxide metabolite of triclabendazole ('Fasinex') on the tegument of mature and immature stages of the liver fluke, Fasciola hepatica. *Parasitology*, **1994**, 108 (Pt 5), 555-67	2.7	67
10	Stereological estimation of Weibel-Palade bodies in the retinal vasculature of normal and diabetic dogs. *Current Eye Research*, **1994**, 13, 705-10	2.9	5
9	Induction of alloxan/streptozotocin diabetes in dogs: a revised experimental technique. *Laboratory Animals*, **1993**, 27, 281-5	2.6	39
8	Fasciola hepatica: tegumental surface changes in adult and juvenile flukes following treatment in vitro with the sulphoxide metabolite of triclabendazole (Fasinex). *Zeitschrift Fü Parasitenkunde (Berlin, Germany)*, **1993**, 79, 529-36		63
7	Fasciola hepatica: the effect of the microtubule inhibitors colchicine and tubulozole-C on the ultrastructure of the adult fluke. *Parasitology*, **1993**, 107 (Pt 3), 297-309	2.7	14
6	Spermatogenesis in Fasciola hepatica: an ultrastructural comparison of the effects of the anthelmintic, thiabendazole (Fasinex) and the microtubule inhibitor, tubulozole. *Invertebrate Reproduction and Development*, **1992**, 22, 139-150	0.7	35
5	Localisation of actin in the liver fluke, Fasciola hepatica. *Zeitschrift Fü Parasitenkunde (Berlin, Germany)*, **1992**, 78, 96-102		29
4	Fasciola hepatica: localization and partial characterization of tubulin. *Zeitschrift Fü Parasitenkunde (Berlin, Germany)*, **1992**, 78, 103-7		13
3	Fasciola hepatica: the effect of the microfilament inhibitor cytochalasin B on the ultrastructure of the adult fluke. *Zeitschrift Fü Parasitenkunde (Berlin, Germany)*, **1991**, 77, 675-85		14
2	Fasciola hepatica: disruption of spermatogenesis by the microfilament inhibitor cytochalasin B. *Zeitschrift Fü Parasitenkunde (Berlin, Germany)*, **1991**, 77, 123-8		12
1	Spermatogenesis and the fine structure of the mature spermatozoon of the liver fluke, Fasciola hepatica (Trematoda: Digenea). *Parasitology*, **1990**, 101 Pt 3, 395-407	2.7	51